URGN
UroGen Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · US
$33.48
−0.80%Year over year
Reported trailing growth
- Revenue
- +100.3%
- EBITDA
- +45.6%
- EBIT
- +46.1%
- EPS
- +40.4%
- Free cash flow
- -28.8%
- Operating cash flow
- -29.1%
Forward estimates
Based on analyst estimates
- Revenue
- +155.7%
- EBITDA
- +341.7%
- EPS
- +204.1%
Three-year CAGR
- Revenue
- +19.5%
- EBITDA
- -43.6%
- EBIT
- -29.0%
- Net income
- -21.0%
- EPS
- -7.8%
- Free cash flow
- -67.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026